Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.62 |
| ▸ | GUSB | P08236 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905071 | 1.00 | PYGL (0.62) | PYGLGUSBNPC1RAB9ATDP1 | |
| SCHEMBL11835199 | 0.85 | BACE1 (0.54) | PYGLNPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1124517 | 0.84 | PYGL (0.62) | PYGLGUSBNPC1RAB9ATDP1 | |
| SCHEMBL1124516 | 0.84 | PYGL (0.62) | PYGLGUSBNPC1RAB9ATDP1 | |
| SCHEMBL7828903 | 0.84 | PYGL (0.62) | PYGLGUSBNPC1RAB9ATDP1 | |
| SCHEMBL6821813 | 0.83 | PTPN11 (0.46) | PYGLGUSBCYP1A2ALDH1A1 | |
| SCHEMBL6821816 | 0.83 | PTPN11 (0.46) | PYGLGUSBCYP1A2ALDH1A1 | |
| SCHEMBL13858839 | 0.83 | PYGL (0.45) | PYGLGUSBNPC1RAB9ATDP1 | |
| SCHEMBL13858840 | 0.83 | PYGL (0.45) | PYGLGUSBNPC1RAB9ATDP1 | |
| Hydrochloric Acid SCHEMBL6821828 | 0.82 | PYGL (0.60) | PYGLGUSBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020108481-A1 | THIAMINE COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 上海日馨生物科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| EP-2822938-B1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RES NEW ZEALAND LIMITED (NZ) | 2019-07-03 | — | — | EP | disclosed |
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-9198420-B2 | Rodenticidal norbormide analogues | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2015-12-01 | — | — | US | disclosed |
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | ANIMAL CONTROL PRODUCTS LIMITED (NZ) | 2015-01-22 | — | — | US | disclosed |
| EP-2822938-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | Landcare Research New Zealand Limited (NZ) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013133726-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2013-09-12 | — | — | WO | disclosed |
| EP-1982716-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8236844-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20060135545-A1 | Benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds | UNIVERSITY RENE DESCARTES PARIS V (FR) | 2006-06-22 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
| EP-1100495-A4 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1100495-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006153-A1 | PROPENAMIDES AS CCR5 MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0579695-A1 | REISSERT COMPOUNDS AS ANTI-HIV AGENTS | THE UPJOHN COMPANY (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992016508-A1 | REISSERT COMPOUNDS AS ANTI-HIV AGENTS | THE UPJOHN COMPANY (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4151303-A | Phenoxyalkylcarboxylic acid compounds and serum-lipid and triglyceride depressing therapeutic compositions | BOEHRINGER MANNHEIM GMBH (DE) | 1979-04-24 | — | — | US | disclosed |
| US-3975435-A | BACTERIOSTATS | GIVAUDAN CORPORATION (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | CASP7, RANBP1, CASP3 | PYGL 755/4885GUSB 1466/4885NPC1 2013/4885 |
| US-20060135545-A1 | Benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds | CBR3, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PYGL 3986/4885GUSB 2812/4885NPC1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.